01.02.2024After seven years as Board member and six years as Chairman of Lonza, Albert Baehny has decided to not stand for re-election at the upcoming Annual General Meeting (AGM) in May 2024. The Board of Directors recognizes the instrumental role of Albert Baehny during his tenure, including leading the company as CEO ad interim during the pandemic and in the current transition to a new CEO.
02.02.2024After seven years as Board member and six years as Chairman of Lonza, Albert Baehny has decided to not stand for re-election at the upcoming Annual General Meeting (AGM) in May 2024. The Board of Directors recognizes the instrumental role of Albert Baehny during his tenure, including leading the company as CEO ad interim during the pandemic and in the current transition to a new CEO.
02.02.2024The life science group Sartorius expects a return to profitable growth in 2024 and a dynamic business development for the five-year period through to 2028. In 2023, soft demand, which...
29.01.2024The life science group Sartorius expects a return to profitable growth in 2024 and a dynamic business development for the five-year period through to 2028. In 2023, soft demand, which...
01.02.2024Not only human health matters to SCHOTT Pharma but also sustainable development and business governance. As a global leader in drug containment solutions and...
26.01.2024Not only human health matters to SCHOTT Pharma but also sustainable development and business governance. As a global leader in drug containment solutions and...
02.02.2024Die zahlreichen Krankmeldungen dürften der Wirtschaft im Jahr 2023 erheblich geschadet haben. Der Verband der forschenden Pharma-Unternehmen (vfa) geht sogar davon aus, dass der Rekordkrankenstand Deutschland in die Rezession drückte.
01.02.2024Der Ausschuss für Humanarzneimittel der Europäischen Arzneimittelbehörde (EMA) rät zur Zulassung des Antibiotikums Exblifep®. Darin ist das bekannte Cephalosporin Cefepim und der Betalaktamase-Inhibitor Enmetazobactam kombiniert.
02.02.2024Das Critical Path Institute (C-Path) hat Dr. Klaus Romero, M.D., M.S., FCP, zu seinem neuen geschäftsführenden Direktor ernannt und Cécile Ollivier, M.S., von Managing-Direktorin, Europa, zur Vizepräsidentin für globale Angelegenheiten befördert.
02.02.2024Chemspeed beschleunigt die Laborautomatisierung und -digitalisierung bei Bruker.
Sie sehen Artikel 17441 bis 17450 von insgesamt 19752